GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » Degree of Financial Leverage

Mirati Therapeutics (Mirati Therapeutics) Degree of Financial Leverage : -3.27 (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Mirati Therapeutics's Degree of Financial Leverage for the quarter that ended in Sep. 2023 was -3.27. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Mirati Therapeutics's Degree of Financial Leverage or its related term are showing as below:

MRTX's Degree of Financial Leverage is not ranked
in the Biotechnology industry.
Industry Median: 0.96 vs MRTX: -3.27

Mirati Therapeutics Degree of Financial Leverage Historical Data

The historical data trend for Mirati Therapeutics's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirati Therapeutics Degree of Financial Leverage Chart

Mirati Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.67 0.62 0.73 0.55

Mirati Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.55 0.39 0.37 -3.27

Competitive Comparison of Mirati Therapeutics's Degree of Financial Leverage

For the Biotechnology subindustry, Mirati Therapeutics's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirati Therapeutics's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Mirati Therapeutics's Degree of Financial Leverage falls into.



Mirati Therapeutics Degree of Financial Leverage Calculation

Mirati Therapeutics's Degree of Financial Leverage for the quarter that ended in Sep. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -12.22 (Sep. 2023) / -13.39 (Sep. 2022) - 1 )/( -764.87 (Sep. 2023) / -744.941 (Sep. 2022) - 1 )
=-0.0874/0.0268
=-3.27***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Mirati Therapeutics  (NAS:MRTX) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Mirati Therapeutics Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirati Therapeutics (Mirati Therapeutics) Business Description

Traded in Other Exchanges
Address
3545 Cray Court, San Diego, CA, USA, 92121
Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
Executives
Jamie Christensen officer: Sr. Vice President, Chief Scie C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey officer: EVP, Chief Commercial Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey officer: Interim CFO 3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty officer: Chief Legal Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer officer: CFO 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121

Mirati Therapeutics (Mirati Therapeutics) Headlines

From GuruFocus